TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immuron Limited ( (AU:IMC) ) has issued an announcement.
Immuron Limited has announced a new research agreement funded by the U.S. Department of Defense to develop two oral therapeutics targeting Campylobacter and Shigella, in collaboration with the Naval Medical Research Command and the Walter Reed Army Institute of Research. This initiative aims to produce hyper-immune bovine colostrum products for the U.S. military, addressing the significant global burden of diarrheal diseases, which impact military readiness and global health. Additionally, Immuron is preparing to release results from a clinical trial on the effectiveness of its ETEC hyperimmune bovine colostrum in maintaining gut health during deployment and travel, highlighting its ongoing efforts to combat antibiotic-resistant enteric pathogens.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. One of its key products, Travelan®, is an orally administered passive immunotherapy designed to reduce the likelihood of contracting travelers’ diarrhea by binding to diarrhea-causing bacteria.
Average Trading Volume: 571,265
Technical Sentiment Signal: Sell
Current Market Cap: A$20.01M
For a thorough assessment of IMC stock, go to TipRanks’ Stock Analysis page.